2026 Buyer's Guide

Weight Loss Injections (2026): Every FDA-Approved Option

Five FDA-approved injectable medications can produce meaningful weight loss in 2026. Three (Wegovy, Zepbound, Saxenda) are FDA-approved specifically for chronic weight management. Two (Ozempic, Mounjaro) are FDA-approved for type 2 diabetes but commonly prescribed off-label for weight loss. Below: side-by-side comparison, how they work, what they cost, and where to get them.

By Ruth Calder · Enforcement Editor

Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed July 2026

9 min read·11 citations

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

About this page

Looking for where to get one? See the best weight loss injections, ranked by price and trust.

Every drug listed below is FDA-approved with a published label on DailyMed (NIH). Mechanism, indication, administration route, dosing, and approval-date data are pulled from our primary-source-verified drug database. Cost data was verified live on July 2026 from manufacturer self-pay portals (NovoCare, LillyDirect), retailer programs (Costco Member Prescription Program via Sesame, Sam's Club Plus, Amazon Pharmacy), and GoodRx. We do not paraphrase indication language.

What are weight loss injections?

Every one of the five weight-loss injections on the US market today is a GLP-1 receptor agonists (one is also a GIP/GLP-1 dual agonist). They are self-administered subcutaneous injections — a small needle into the fat layer of the abdomen, thigh, or back of the upper arm — and they reduce appetite via the GLP-1 signaling pathway plus slow gastric emptying. Three are FDA-approved for chronic weight management; two are FDA-approved for type 2 diabetes and prescribed off-label for weight loss when the weight-loss-indicated drugs are unavailable, denied by insurance, or contraindicated. The class history started with Byetta (exenatide) in 2005 for type 2 diabetes; Saxenda was the first weight-management indication in December 2014; Wegovy, Zepbound, and Foundayo followed.

For the deeper biology of GLP-1 — what the hormone is, how the receptor works, and the four physiologic actions (insulin secretion, glucagon suppression, gastric emptying, central appetite suppression) — see our GLP-1 complete guide. For oral weight loss medications (Foundayo, Rybelsus, Qsymia, Contrave, Xenical), see our FDA-approved weight loss medications hub (which compares pills vs injections side-by-side).

Every FDA-approved weight loss injection, compared

All five injections side-by-side. Pivotal trial efficacy cited from the canonical phase 3 publication for each drug; full PMID citations live in our bariatric vs GLP-1 decision guide.

Brand	Generic	Indication	Schedule	Pivotal trial result	Guide
Wegovy	Semaglutide 2.4 mg	Weight management; CV risk reduction	Once weekly (0.25 → 2.4 mg)	~14.9% body-weight loss at 68 wk (STEP-1, NEJM 2021)	Wegovy →
Zepbound	Tirzepatide	Weight management; OSA in obesity	Once weekly (2.5 → 15 mg)	~20.9% body-weight loss at 72 wk on 15 mg (SURMOUNT-1, NEJM 2022)	Zepbound →
Saxenda	Liraglutide 3 mg	Chronic weight management	Once-daily injection (0.6 → 3.0 mg titration)	mean loss of roughly 5–8% by week 56 (SCALE Obesity / Prediabetes, PMID 26132939)	DailyMed →
Ozempic	Semaglutide (lower-dose)	Type 2 diabetes (off-label for weight loss)	Once weekly (0.25 → 2 mg)	A1C ↓ ~1.5-1.8% (SUSTAIN); ~12% off-label weight loss	Ozempic →
Mounjaro	Tirzepatide	Type 2 diabetes (off-label for weight loss)	Once weekly (2.5 → 15 mg)	A1C ↓ ~2.0-2.5% (SURPASS-2); ~15-22% off-label weight loss	Mounjaro →

What weight loss injections cost in 2026

What a branded injection lists at swings hard depending on where you buy it. Read off the manufacturers' and retailers' own pages on 9 May 2026:

Wegovy (semaglutide)

NovoCare self-pay: $299/month (standard pen, all doses 0.25–2.4 mg)
NovoCare HD pen 7.2 mg: $399/month
Wegovy oral pill 1.5/4 mg: $149/month
Costco CMPP via Sesame: $349/month (new pt $199 × 2 mo)
Sam's Club: $499/month via copay program
With insurance copay savings card: as little as $25/month

Zepbound (tirzepatide)

LillyDirect vials self-pay (effective Dec 1, 2025): $299 / $399 / $449 by strength
LillyDirect KwikPen self-pay: $299–$699 by strength
Sam's Club KwikPen: $299/$399/$499/$699
GoodRx coupon path: $299/month (manufacturer-funded)

Saxenda (liraglutide)

Brand list: ~$1,300/month
Generic liraglutide (Teva, launched Aug 28 2025): pricing varies by pharmacy
Manufacturer copay savings card: as little as $25/month for commercially insured

Ozempic (off-label) + Mounjaro (off-label)

Ozempic NovoCare new patient: $199/mo for first 2 months; $349 standard
Ozempic GoodRx: $149/month (oral 1.5 mg) / pen via Novo
Mounjaro: no DTC self-pay program; copay savings card for commercial
Off-label use is rarely insurance-covered for weight in someone without type 2 diabetes

For the live channel-by-channel pricing index across every channel + compounded options ($99–$400/mo), see our GLP-1 pricing index. IRS Publication 502 makes both branded and compounded GLP-1s HSA- and FSA-eligible once a prescription exists.

How to get a weight loss injection (telehealth, retail, insurance)

Three primary channels:

Insurance + traditional prescriber. Your own doctor or an obesity-medicine specialist writes it, a pharmacy fills it, and your insurer decides whether its prior-authorization rules are satisfied. See our Cigna PA guide and Aetna PA guide for verbatim payer policy. Three things get under-documented more than anything else: Cigna's list of 11 qualifying comorbidities, Aetna's demand for six months of a behavioral program first, and the switch CVS Caremark made to Wegovy-preferred in July 2025.
GLP-1 telehealth providers. An online clinic paired with a 503A pharmacy. Paying cash for compounded semaglutide or tirzepatide usually runs $99 to $400 a month. See our best semaglutide providers and best tirzepatide providers for ranked options. Note: the FDA's enforcement-discretion grace period for compounded semaglutide ended February 2025 — the regulatory landscape is unsettled.
Direct-to-consumer manufacturer pharmacies. NovoCare (Wegovy/Ozempic), LillyDirect (Zepbound/ Mounjaro/Foundayo), Costco CMPP via Sesame partner, Sam's Club Plus, Amazon Pharmacy. Cash-pay only — not eligible for insurance.

With the medicine in hand, inject the way the label says. Our step-by-step injection technique guide for every common pen and vial format, including the three FDA-approved injection sites (abdomen, thigh, back of upper arm), needle gauge, depth, angle, and the site-rotation schedule that minimizes lipohypertrophy.

Compare vetted GLP-1 telehealth providers

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

Cash-pay pricing · HSA/FSA accepted · every partner checked by our editors

7.8

Oak

Semaglutide at $119/month, 37% below the typical price

Starting price: $119/mo

Get started →Read review Oak →

6.4

Bodybuilding Health+

Seeing what it charges before you answer any medical questions

Starting price: $179/mo

Get started →Read review Bodybuilding Health+ →

8.0

Lttl

Starting below a standard dose, with microdose tiers

Starting price: $119/mo

Get started →Read review Lttl →

6.4

Direct Meds

Compounded semaglutide at $249/month

Starting price: $249/mo

Get started →Read review Direct Meds →

7.4

MEDGm

Month-to-month compounded semaglutide at $179 with the partner pharmacies named

Starting price: $179/mo

Get started →Read review MEDGm →

5.7

HumeCare+

An oral route if you will not self-inject

Starting price: $199/mo

Get started →Read review HumeCare+ →

Provider	Starting price	Best for
7.8Oak	$119/mo	Semaglutide at $119/month, 37% below the typical price	Get started →
6.4Bodybuilding Health+	$179/mo	Seeing what it charges before you answer any medical questions	Get started →
8.0Lttl	$119/mo	Starting below a standard dose, with microdose tiers	Get started →
6.4Direct Meds	$249/mo	Compounded semaglutide at $249/month	Get started →
7.4MEDGm	$179/mo	Month-to-month compounded semaglutide at $179 with the partner pharmacies named	Get started →
5.7HumeCare+	$199/mo	An oral route if you will not self-inject	Get started →

Read review Oak →Read review Bodybuilding Health+ →Read review Lttl →Read review Direct Meds →Read review MEDGm →Read review HumeCare+ →

Frequently Asked Questions

On published efficacy, Zepbound at 15 mg of tirzepatide leads: roughly 20.9% mean body-weight loss by week 72 in SURMOUNT-1 (NEJM 2022). Wegovy, semaglutide at 2.4 mg, reached about 14.9% by week 68 in STEP-1 (NEJM 2021), and SURMOUNT-5 (NEJM 2025) put the two head to head and confirmed tirzepatide ahead. Saxenda, liraglutide 3.0 mg, is the older drug and lands around 5–8% at 56 weeks. Which is best for you is a separate question, decided by what you tolerate, what your plan covers, and what you can afford.

Almost certainly. The big chains all carry them — CVS, Walgreens, Rite Aid, Costco and Sam's Club will each dispense an approved weight-loss injection against a valid prescription, and telehealth sellers ship nationwide. Lilly sends Zepbound out through LillyDirect's partner pharmacies; Novo sends Wegovy through NovoCare. Amazon Pharmacy does same-day delivery in more than 3,000 cities.

Their safety profile is published and well characterized. The complaints are overwhelmingly from the gut — nausea and vomiting, diarrhea or constipation, abdominal pain — and they peak while the dose is still climbing. A boxed warning about thyroid C-cell tumors sits on Wegovy, Zepbound and Saxenda alike — drawn from rodent work whose bearing on humans remains disputed. Beyond that the documented concerns are gallbladder disease, pancreatitis, ileus, and muscle loss where weight comes off quickly.

Among branded pens bought with cash, Zepbound opens lowest — $299 a month for the 2.5 mg starting dose through LillyDirect Self Pay, rising to $399 at 5 mg and $449 above that if you refill inside 45 days. NovoCare puts Wegovy at $349 a month standard, though a patient new to the offer pays $199 for the first two fills, which is the lowest entry price on the market. Costco's Member Prescription Program lists $349 a month for Wegovy and Ozempic through its Sesame partner. With commercial cover and a copay card, Wegovy or Saxenda can come down to $25. Compounded semaglutide and tirzepatide from licensed 503A pharmacies usually sit between $99 and $400 — cheaper still, and not FDA-approved.

No — both are licensed for type 2 diabetes alone. The identical molecules are sold for weight management under other names: semaglutide as Wegovy, tirzepatide as Zepbound. A prescriber may write either off-label for weight, which is lawful, but an insurer will seldom pay for it on that basis.

Two oral GLP-1s hold FDA approval as of 2026 — Foundayo, approved April 2026 for weight management, and Rybelsus, which is diabetes-only — alongside three older non-GLP-1 tablets in Qsymia, Contrave and Xenical or alli. On the published trials the injectables still take off more weight than anything oral, but Foundayo is too recent for that comparison to be fair yet.

References

1.U.S. Food and Drug Administration / manufacturer label. Wegovy — FDA Prescribing Information: what it is licensed for, how it is dosed, and the boxed warning quoted word for word off the current label. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
2.U.S. Food and Drug Administration / manufacturer label. Zepbound — FDA Prescribing Information: what it is licensed for, how it is dosed, and the boxed warning quoted word for word off the current label. DailyMed, U.S. National Library of Medicine. 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
3.U.S. Food and Drug Administration / manufacturer label. Ozempic — FDA Prescribing Information: what it is licensed for, how it is dosed, and the boxed warning quoted word for word off the current label. DailyMed, U.S. National Library of Medicine. 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
4.U.S. Food and Drug Administration / manufacturer label. Mounjaro — FDA Prescribing Information: what it is licensed for, how it is dosed, and the boxed warning quoted word for word off the current label. DailyMed, U.S. National Library of Medicine. 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
5.U.S. Food and Drug Administration / Novo Nordisk label. Saxenda (liraglutide 3 mg) — FDA Prescribing Information: the dose ladder, what it is licensed for, and the boxed warning quoted word for word off the current label). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
6.Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — ~20.9% mean body-weight reduction at 72 weeks (15 mg). New England Journal of Medicine. 2022. PMID: 35658024.
7.Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — ~14.9% mean body-weight reduction at 68 weeks (2.4 mg). New England Journal of Medicine. 2021. PMID: 33567185.
8.Garvey WT, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) — head-to-head superiority of tirzepatide over semaglutide. New England Journal of Medicine. 2025. PMID: 40334173.
9.Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes) — ~5-8% mean body-weight reduction at 56 weeks. New England Journal of Medicine. 2015. PMID: 26132939.
10.Novo Nordisk. NovoCare self-pay for Wegovy and Ozempic — the cash pen prices, read off the live page in July 2026. novocare.com. 2026. https://www.novocare.com/
11.Eli Lilly and Company. LillyDirect self-pay for Zepbound single-dose vials — cash prices by strength, read off the live page in July 2026. lilly.com/lillydirect. 2026. https://lillydirect.lilly.com/